Przejdź do zawartości
Merck

Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants.

eLife (2020-12-03)
Adam R Blanden, Xin Yu, Alan J Blayney, Christopher Demas, Jeung-Hoi Ha, Yue Liu, Tracy Withers, Darren R Carpizo, Stewart N Loh
ABSTRAKT

Missense mutations in the p53 DNA-binding domain (DBD) contribute to half of new cancer cases annually. Here we present a thermodynamic model that quantifies and links the major pathways by which mutations inactivate p53. We find that DBD possesses two unusual properties-one of the highest zinc affinities of any eukaryotic protein and extreme instability in the absence of zinc-which are predicted to poise p53 on the cusp of folding/unfolding in the cell, with a major determinant being available zinc concentration. We analyze the 20 most common tumorigenic p53 mutations and find that 80% impair zinc affinity, thermodynamic stability, or both. Biophysical, cell-based, and murine xenograft experiments demonstrate that a synthetic zinc metallochaperone rescues not only mutations that decrease zinc affinity, but also mutations that destabilize DBD without impairing zinc binding. The results suggest that zinc metallochaperones have the capability to treat 120,500 patients annually in the U.S.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Anti-p53 (Ab-3) (Mutant) Mouse mAb (PAb240), liquid, clone PAb240, Calbiochem®
Sigma-Aldrich
Anti-p53 (Ab-5) (Wild type) Mouse mAb (PAb1620), liquid, clone PAb1620, Calbiochem®